BioMarin's Loss Masks Near-Target Revenue
California biopharma suppliers should weigh the gap between reported losses and adjusted earnings when judging customer finances.
Updated on Nov. 2, 2026 in Economic Indicators
BioMarin Pharmaceutical, a San Rafael, California-based rare disease biopharmaceutical company, reported a third-quarter net loss of $122.8 million, or 63 cents per share, on Monday. Adjusted earnings were 23 cents per share and revenue reached $1.02 billion, a result that matters to California's life sciences employers and suppliers.
Why it matters
The quarter's headline loss sits against adjusted earnings and revenue that landed near analyst expectations, which signals that the gap is driven by reported charges rather than a sudden collapse in sales. For operators in the state's biotech supply chain, the spread between GAAP and adjusted figures is the number to read closely when judging how a major employer is actually spending and earning.
BioMarin reported a $122.8 million net loss and 63-cent loss per share against analyst expectations of a 9-cent loss, while revenue of $1.02 billion came in just below the $1.03 billion forecast by eight analysts. The company guided full-year earnings to $2.80 to $3.10 per share and revenue to $3.8 billion to $3.9 billion.
The players
BioMarin Pharmaceutical
A San Rafael, California-based rare disease biopharmaceutical company that develops therapies for small patient populations.
Zacks Investment Research
An independent equity research firm whose analyst consensus is widely used as a benchmark for quarterly earnings expectations.
The details
Earnings were reported on a GAAP basis as a loss, but adjusted earnings of 23 cents per share presented a materially different picture, a common divergence for biopharmaceutical companies whose reported results absorb non-cash or one-time items. Revenue of $1.02 billion tracked closely with analyst estimates. Management's full-year outlook, with earnings of $2.80 to $3.10 per share and revenue of $3.8 billion to $3.9 billion, frames the quarter as one data point within a larger annual trajectory.
Timeline
Monday, November 2, 2026: BioMarin released third-quarter earnings results.
Third quarter 2026: Period in which the reported loss and revenue were recorded.
Last 12 months: Shares rose slightly more than 7% over this window.
Market Landscape
Consensus-based comparison through Zacks Investment Research is the standard benchmark against which biopharmaceutical quarters are judged, and BioMarin's revenue landed within a few percent of that benchmark. The result sits against a share price that has declined 3% year to date while gaining about 7% over twelve months, placing investor sentiment in a relatively steady range.
Operators supplying or competing with California's biopharmaceutical sector should weigh the gap between reported and adjusted earnings when evaluating customer demand and payment reliability. Procurement and finance teams tracking this segment should monitor whether the company's full-year guidance holds in the next quarter's filing.
The takeaway
Read a company's adjusted and GAAP results side by side before treating either as the full picture of its financial health. Set a reminder to compare the next quarter's results against the company's $2.80 to $3.10 full-year earnings guidance to see whether the outlook is being met.
Further reading
For the broader backdrop on how company earnings feed into state-level economic signals, see Economic Indicators in California.
Source note: This article includes information reported by San Francisco Gate.
